Department of Thoracic Surgery, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.
Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.
Nat Biomed Eng. 2021 Jun;5(6):586-599. doi: 10.1038/s41551-021-00746-5. Epub 2021 Jun 15.
The low abundance of circulating tumour DNA (ctDNA) in plasma samples makes the analysis of ctDNA biomarkers for the detection or monitoring of early-stage cancers challenging. Here we show that deep methylation sequencing aided by a machine-learning classifier of methylation patterns enables the detection of tumour-derived signals at dilution factors as low as 1 in 10,000. For a total of 308 patients with surgery-resectable lung cancer and 261 age- and sex-matched non-cancer control individuals recruited from two hospitals, the assay detected 52-81% of the patients at disease stages IA to III with a specificity of 96% (95% confidence interval (CI) 93-98%). In a subgroup of 115 individuals, the assay identified, at 100% specificity (95% CI 91-100%), nearly twice as many patients with cancer as those identified by ultradeep mutation sequencing analysis. The low amounts of ctDNA permitted by machine-learning-aided deep methylation sequencing could provide advantages in cancer screening and the assessment of treatment efficacy.
循环肿瘤 DNA(ctDNA)在血浆样本中的含量低,使得分析 ctDNA 生物标志物以检测或监测早期癌症具有挑战性。在这里,我们表明,通过机器学习分类器辅助的深度甲基化测序,可以在低至 10000 稀释倍数的情况下检测到肿瘤衍生的信号。对来自两家医院的总共 308 名可手术切除肺癌患者和 261 名年龄和性别匹配的非癌症对照个体进行了检测,该检测方法在疾病分期为 IA 到 III 期的患者中检测到 52-81%,特异性为 96%(95%置信区间 (CI) 93-98%)。在 115 名个体的亚组中,该检测方法以 100%的特异性(95%CI 91-100%),几乎可以识别出两倍数量的癌症患者,而这些患者是通过超高深度突变测序分析识别的。机器学习辅助深度甲基化测序允许的低数量 ctDNA 可能在癌症筛查和治疗效果评估方面具有优势。